About Cytochrome b-c1 complex subunit 2, mitochondrial
Cytochrome b-c1 complex subunit 2, mitochondrial (UQCRC2) is a protein
from Homo sapiens identified by UniProt accession
P22695, 453 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | Cytochrome b-c1 complex subunit 2, mitochondrial |
| UniProt accession | P22695 |
| Gene | UQCRC2 |
| Organism | Homo sapiens |
| Length | 453 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (93)
Diseases linked to this target (Open Targets).
- Isolated CoQ-cytochrome C reductase deficiency · score 0.72
- neurodegenerative disease · score 0.42
- mitochondrial disease · score 0.18
- gonorrhea · score 0.08
- cancer · score 0.06
- neoplasm · score 0.06
- acute myeloid leukemia · score 0.06
- drug use measurement · score 0.02
- metabolic syndrome · score 0.02
- carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P22695-F1 | alphafold | PREDICTED | 90.06 | — |
Amino-acid sequence (453 residues)
MKLLTRAGSF SRFYSLKVAP KVKATAAPAG APPQPQDLEF TKLPNGLVIA SLENYSPVSR IGLFIKAGSR YEDFSNLGTT HLLRLTSSLT TKGASSFKIT RGIEAVGGKL SVTATRENMA YTVECLRGDV DILMEFLLNV TTAPEFRRWE VADLQPQLKI DKAVAFQNPQ THVIENLHAA AYRNALANPL YCPDYRIGKV TSEELHYFVQ NHFTSARMAL IGLGVSHPVL KQVAEQFLNM RGGLGLSGAK ANYRGGEIRE QNGDSLVHAA FVAESAVAGS AEANAFSVLQ HVLGAGPHVK RGSNTTSHLH QAVAKATQQP FDVSAFNASY SDSGLFGIYT ISQATAAGDV IKAAYNQVKT IAQGNLSNTD VQAAKNKLKA GYLMSVESSE CFLEEVGSQA LVAGSYMPPS TVLQQIDSVA NADIINAAKK FVSGQKSMAA SGNLGHTPFV DEL
Explore Cytochrome b-c1 complex subunit 2, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets